

## **Halma plc ('Halma' or the 'Group')**

### **Acquisition**

Halma, the global group of life-saving technology companies, today announces that it has acquired Rovers Medical Devices B.V. ("Rovers").

Headquartered in Oss in the Netherlands, Rovers designs and manufactures sample collection devices used in the prevention and diagnostics of cervical cancer. Rovers' products are principally for professional use and include its Cervex-Brush®, widely recognised as the gold standard for cervical cancer screening. Rovers' products are used in more than 90 countries, and are sold primarily to medical diagnostic companies, as well as medical distributors, laboratories, research institutes and governments.

The initial consideration for Rovers is €85m (approximately £73m), on a cash- and debt-free basis, which will be paid in cash and funded from Halma's existing facilities. An additional consideration of up to €6m (approximately £5m) is payable in cash, based on Rovers' performance in the period to 31 March 2025.

Rovers' unaudited revenue for the 12 months to 31 December 2023 was €12.0m (approximately £10.3m), with Return on Sales more than double Halma's target range of 18-22%. Rovers will be a standalone company within Halma's Healthcare sector, led by its current management team.

Marc Ronchetti, Group Chief Executive of Halma, said:

"Rovers will broaden the range of markets we serve in women's health and further strengthen our Healthcare sector's position in cancer diagnosis products. We are excited by the opportunities we see to increase Rovers' positive impact on public health. We expect its future growth to be driven by increasing global cervical screening rates, supporting the World Health Organization's strategy to accelerate the early detection of cervical cancer."

Roel Leenders, Chief Executive Officer of Rovers, said:

"We want to contribute to the prevention of cancer on a global scale. This mission strongly aligns to Halma's when it comes to improving quality of care for patients. Many physicians work with us to develop the highest quality screening products that are most effective for their patients. By joining the Halma group, Rovers can grow to the next level, adding talent development and commercial opportunities while collaborating with a global group of like-minded businesses, that will help us to enable better screening and diagnostics for patients worldwide."

For further information, please contact:

#### **Halma plc**

Marc Ronchetti, Group Chief Executive	+44 (0)1494 721111
Steve Gunning, Group Chief Financial Officer	
Charles King, Head of Investor Relations	+44 (0) 7776 685948
Clayton Hirst, Director of Corporate Affairs	+44 (0) 7384 796 013

#### **MHP**

Oliver Hughes / Rachel Farrington / Ollie Hoare	+44 (0)20 3128 8100
---	---------------------

A copy of this announcement, together with other information about Halma, is available at [www.halma.com](http://www.halma.com).

#### **About Halma**

Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day. Its purpose defines the three broad markets it operates in:

- Health - Meeting the increasing demand for better healthcare as chronic illness rises, driven by growing and ageing populations and lifestyle changes.
- Environment - Addressing the impacts of climate change, pollution and waste, protecting life-critical resources and supporting scientific research.
- Safety - Protecting people's safety and the environment as populations grow and enhancing worker safety.

It employs over 8,000 people in more than 20 countries, with major operations in the UK, Mainland Europe, the USA and Asia.

it employs over 8,000 people in more than 20 countries, with major operations in the UK, mainland Europe, the USA and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.

Halma has been named as one of Britain's Most Admired Companies for the past five years.

For more information [www.halma.com](http://www.halma.com)

**ENDS**

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ACQJBMRTMTMMBLI